Information

2023/01/13

Resuming normal office operations

2023/01/11

2023 New Year Greeting

2023/01/04

FAQ for Our Disclosure on December 27, 2022, “GNI Group and Catalyst Biosciences Signed Agreements to Advance Liver Fibrosis Drug Development”

2022/12/20

Notice of COVID-19 infection of our employees and suspension of telephone reception

2022/11/29

FY2022 Q3 Analyst Call Q&A Summary

2022/08/25

FY2022 Q2 Analyst Call Q&A Summary

2022/06/11

Chief Scientific Officer of Cullgen Inc. will be speaking at the 30th Annual Meeting of the Japanese Breast Cancer Society

2022/06/11

Beijing Continent enrolls the first subject of pirfenidone capsules Phase III clinical trial for pneumoconiosis

2022/05/24

FY2022 Q1 Analyst Call Q&A Summary

2022/04/15

GNI Group FY2021 Annual General Meeting Q&A Summary